Internet Pioneer In...
Health Care: Drugs
Cadence Pharmaceuticals Inc. (CADX: NASDAQ)
$2.74 0.04 | 1.29%
06/04/12 - 03:44 PM ET
Company Cash Flow
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -93.02M | -56.64M | -45.49M | -57.10M |
| Operating Gains/Losses | -66.00K | 55.00K | 6.70K | 31.09K |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | -2.70M | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease in Inventories | -6.48M | -485.00K | 0.00 | 0.00 |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | 360.00K | 653.00K | -1.93M | 3.02M |
| (Decrease) Increase In Other Current Liabilities | 3.85M | -82.00K | -2.72M | -5.62M |
| (Increase) Decrease In Other Working Capital | 1.29M | -15.00M | 0.00 | 0.00 |
| Other Non-Cash Items | 14.86M | 12.10M | 7.78M | 8.50M |
| Net Cash From Continuing Operations | -78.15M | -58.86M | -42.05M | -49.69M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -78.15M | -58.86M | -42.05M | -49.69M |
| Sale of Property, Plant & Equipment | 66.00K | 3.00K | 0.00 | 195.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 0.00 | 0.00 | 4.58M | 0.00 |
| Purchases of Property, Plant & Equipment | -2.73M | -3.75M | -3.27M | -1.74M |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | -82.68M | -24.20M | -10.74M | 0.00 |
| Other Cash from Investing Activities | -3.80M | 1.35M | 1.05M | 134.00K |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -29.14M | -21.85M | -8.38M | -1.61M |
| Issuance of Debt | 3.43M | 29.59M | 0.00 | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 78.75M | 93.79M | 86.36M | 49.15M |
| Repayment of Long-Term Debt | -4.45M | -6.35M | -7.69M | -5.62M |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Cash From Financing Activities | 77.73M | 117.03M | 78.66M | 43.53M |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | -29.57M | 36.32M | 28.23M | -7.77M |
Portfolios with CADX
- Portfolio NameUser Type
- Contributor8 Stocks Below $10 To Avoid
- Contributor10 Most Shorted Stocks in B...
- ContributorRelative Strength Stocks 09...
- Usergrainey Portfolio 1
- Useryourguess Portfolio 1
- Userlives288
- UserCarl Nicola Portfolio 1
- Userron stewart
Latest CADX Headlines from TheStreet
- 8 Stocks Under $10 to Avoid at All Costs 12.23.11 | 12:12 pm
- Pacira: Exparel Approval Easy, Selling Painkiller Harder Challenge 10.31.11 | 11:10 am
- 5 Stocks Showing Relative Strength in a Weak Market 09.22.11 | 02:09 pm
- Biotech Stock Mailbag: Cadence Pharma 03.11.11 | 07:03 am
- Biotech Sector Weekly Rewind 11.06.10 | 09:11 am
- Cadence CEO Discusses Q3 2010 Results - Earnings Call Transcript 11.05.10 | 02:11 pm
- Cadence: When A Drug Approval Sinks Stock 11.03.10 | 10:11 am
- FDA Ends October With Drug Approvals, Rejection 11.01.10 | 07:11 am
- Biotech Stock Mailbag: Exact Sciences 10.15.10 | 07:10 am
- 21 Drugs Facing FDA Approval Decisions 08.31.10 | 08:08 am
Press Releases for CADX
- Cadence Pharmaceuticals Announces Proposed Public Offering Of Common Stock - PR Newswire 11.08.10 | 06:11 am
Partner Headlines for CADX
- Cadence: Not Altering Sales Projections Or Rating In Aftermath Of Product Recall - Seeking Alpha 02.08.12 | 09:02 am
- Cadence Pharmaceuticals: Good For Patients, Bad For Investors - Seeking Alpha 12.26.11 | 08:12 am
- Wedbush Lowers Cadence PT to $10 from $15 - Benzinga 11.23.11 | 01:11 pm
- Company News for November 18, 2011 - Corporate Summary - Zacks 11.18.11 | 10:11 am
- Options Brief: Cadence Pharmaceuticals - Benzinga 07.15.11 | 01:07 pm
- Cadence: Not Unduly Concerned About ANDA Filing Against Ofirmev - Seeking Alpha 07.05.11 | 09:07 am
- 6 Speculative Biotech Stocks Smart Money Loves - Seeking Alpha 05.23.11 | 09:05 am
- Top 15 Most Undervalued Biotech Stocks By Analyst Target Price - Seeking Alpha 04.08.11 | 03:04 pm
- Future Biotech Superstars - Seeking Alpha 03.30.11 | 09:03 am
- Cadence Pharmaceuticals: A Rising Star - Seeking Alpha 03.13.11 | 09:03 am
